Table 1.
Baseline characteristics
| Characteristic | All | GMG | OMG | Remission | p‐value |
|---|---|---|---|---|---|
| n (%) | 200 | 119 | 39 | 42 | |
| Age, year, mean (SD) | 58 (17) | 56 (17) | 60 (15) | 61 (17) | .235 |
| Age at disease onset, mean (SD) | 48 (20) | 45 (21) | 53 (17) | 52 (20) | .032 |
| Female sex, n (%) | 107 (53.5) | 76 (63.9) | 12 (30.8) | 19 (45.2) | .001 |
| Disease duration, year, median (IQR) | 6 (2–15) | 7 (3–16) | 3 (2–10) | 6 (2–10) | .014 |
| Antibody status, n (%) (1 missing) | |||||
| AchR | 166 (83.4) | 98 (83.1) | 30 (76.9) | 38 (90.5) | .258 |
| MuSK | 6 (3.0) | 5 (4.2) | 1 (2.6) | — | .535 |
| Negative | 27 (13.6) | 15 (12.7) | 8 (20.5) | 4 (9.5) | .322 |
| Medication, n (%) | |||||
| Cholinesterase inhibitors | 173 (86.5) | 107 (89.9) | 37 (94.9) | 29 (69.0) | .001 |
| Glucocorticoids | 111 (55.5) | 68 (57.1) | 23 (59.0) | 20 (47.6) | .502 |
| Immunosuppressants | 116 (58.0) | 81 (68.1) | 10 (25.6) | 25 (59.5) | <.001 |
| None | 4 (2.0) | 1 (0.8) | – | 3 (7.1) | .064 |
| Thymectomy, n (%) (9 missings) | 99 (51.8) | 68 (59.6) | 9 (24.3) | 22 (55.0) | .001 |
| Thymoma | 24 (24.2) | 18 (75.0) | 3 (12.5) | 3 (12.5) | .380 |
| Thymus hyperplasia | 31 (31.3) | 21 (67.7) | 2 (6.5) | 8 (25.8) | .736 |
| Comedication, n (%) | |||||
| Antidepressants | 18 (9.0) | 15 (12.6) | 2 (5.1) | 1 (2.4) | .089 |
| NSAIDs | 13 (6.5) | 8 (6.7) | 2 (5.1) | 3 (7.1) | .924 |
| Opioids | 8 (4.0) | 7 (5.9) | 1 (2.6) | 0 (0.0) | .217 |
GMG, generalized myasthenia gravis; OMG, ocular myasthenia gravis; AchR, acetylcholine receptor; MuSK, muscle‐specific tyrosine kinase.
p‐values refer to overall group comparisons of patients with generalized MG, ocular MG, and pharmacological remission.